An observational study in Atopic Dermatitis, Psoriasis and Hidradenitis Suppurativa (HS), sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Dermatitis, Atopic with a site in Italy — 15 open to participants now, 27 under way, 9 of them phase 3. Dermatitis, Atopic · Italy.
Among the 83 studies in Dermatitis, Atopic with a site in Italy, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 17 of the 26 other live ones, and was the 83rd registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →15 of the 83 studies in Dermatitis, Atopic with a site in Italy are open now. Recruiting first, the newest first:
University of Roma La Sapienza · Sites in Italy
Ages 1 wk–5 mo · Healthy volunteers
Sanofi · Sites in Italy, United States, Canada and 6 more countries
Ages 12+
Biokosmes Srl · Sites in Italy
Ages 6 mo–65 yrs
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 14 more countries
Ages 18–100
Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse · Sites in Italy
Ages 18–99
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 44 · Phase 4 3
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 694 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 350 across the 69 interventional studies, 784 across the 14 observational. Of the 55 that completed or were terminated, 32 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 83 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 237 studies on the registry; 81 are open to participants now.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
4 of the studies in Dermatitis, Atopic with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06239311Phase 3medac GmbHEfficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | 2026-11 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Dermatitis, Atopic with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine whether the gut bacteria of adults with inflammatory or immune-mediated skin diseases differ from those of healthy adults. It will include people with atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid, as well as healthy controls.
Participants will provide a stool sample and complete a short food diary. The study team will analyze the bacteria in the samples and compare the results between the disease groups and healthy controls. Participants with a skin disease will be asked to provide a second stool sample and complete follow-up assessments about six months later; healthy controls will provide one sample. The study will also examine whether changes in gut bacteria are related to skin disease severity, diet, and other collected health information.
Adults aged 18 years or older with one of eight specialist-confirmed inflammatory or immune-mediated skin diseases, plus healthy adult controls without those diseases. Participants are recruited through the Dermatology service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 years or older with dermatologist-confirmed atopic dermatitis. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older with dermatologist-confirmed psoriasis. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older with dermatologist-confirmed hidradenitis suppurativa. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older with dermatologist-confirmed vitiligo. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older with dermatologist-confirmed acne. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older with dermatologist-confirmed pemphigus. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older with dermatologist-confirmed bullous pemphigoid. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Adults aged 18 years or older who do not have the skin diseases studied. Participants provide one stool sample and complete study assessments at baseline.
dults aged 18 years or older with dermatologist-confirmed alopecia areata. Participants provide a stool sample and complete study assessments at baseline and about six months later.
Relative abundance of Bifidobacteriaceae in stool
Compare the relative abundance of the bacterial family Bifidobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. Relative abundance is the number of sequences assigned to Bifidobacteriaceae divided by the total number of bacterial sequences.
Time frame: Baseline (T1)
Relative abundance of Enterobacteriaceae in stool in the combined patient group
Compare the relative abundance of Enterobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls.
Time frame: Baseline (T1)
Relative abundance of Bifidobacteriaceae by skin-disease group
Compare stool Bifidobacteriaceae relative abundance between each disease group-atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, and bullous pemphigoid-and healthy controls.
Time frame: Baseline (T1)
Relative abundance of Enterobacteriaceae by skin-disease group
Compare stool Enterobacteriaceae relative abundance between each of the eight disease groups and healthy controls.
Time frame: Baseline (T1)
Change in stool Bifidobacteriaceae and Enterobacteriaceae over time
Assess within-person changes in the relative abundance of Bifidobacteriaceae and Enterobacteriaceae between T1 and T2 in participants with skin disease.
Time frame: Baseline (T1) to 6 months (T2)
Associations between gut bacteria and disease-related measures
Explore associations between Bifidobacteriaceae and Enterobacteriaceae relative abundance and disease activity scores, psychological impact scores, available routine laboratory markers, dietary intake, and anthropometric measures, as specified in the protocol.
Time frame: Baseline (T1) and 6 months (T2)
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.
Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 27 months is below that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico →